(2024)
Advances in Glucagon: pp.
76-89.
Chapter 8
Dose–response effects on HbA1c
and bodyweight reduction
of survodutide, a dual glucagon/GLP‑1 receptor agonist, compared
with placebo and open‑label semaglutide in people with type 2
diabetes: a randomised clinical trial